Azenta Inc
AZTA
ISIN US1143401024 / Valor 1568240
Azenta Inc
UMushroom community rating:
About company
Azenta Inc, formerly known as Brooks Automation, is a leading provider in the life sciences sector, specializing in comprehensive sample management and genomic services for the biotech, pharmaceutical, and academic research markets. The company has developed a robust quality management system to meet the diverse needs of its customers, emphasizing its commitment to supporting scientific research and development. Azenta has been recognized for its innovative solutions, such as the Azenta Cryo Store Pico and the BioArc™ Ultra, which have garnered industry accolades for their design and functionality. These products exemplify Azenta's focus on developing automated, high-density, and eco-friendly ultracold sample management systems. Additionally, the company's selection by the Lupus Research Alliance to provide sample management services for the Lupus Nexus patient registry highlights Azenta's capability in supporting critical research initiatives. Through its advanced technologies and services, Azenta aims to enhance the efficiency and effectiveness of sample management in the life sciences, contributing to the acceleration of scientific discovery and therapeutic development.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.08.2024):
Revenue Growth
Azenta Inc. reported revenue of $159 million for the second quarter ended March 31, 2024, reflecting a 7% increase year over year. This growth was driven by higher revenues in the B Medical Systems and Sample Management Solutions segments. Organic revenue also grew by 7%, excluding the impacts from foreign exchange.
Segment Performance
The Sample Management Solutions segment generated $74 million in revenue, marking a 4% increase year over year. Organic revenue for this segment grew by 3%, primarily due to strong performance in large-automated Store Systems and Sample Repository Solutions, despite a decline in the Consumables and Instruments product line.
Multiomics and B Medical Systems
Multiomics revenue remained flat at $62 million compared to the same quarter last year, with a 1% organic revenue growth driven by Gene Synthesis services. B Medical Systems saw a significant revenue increase to $23 million, up 51% year over year, largely due to additional cold chain solution orders.
GAAP Earnings
Azenta Inc. reported an operating loss of $147 million for the second quarter of fiscal year 2024, with an operating margin of (92.3%). The gross margin improved by 400 basis points year over year to 39.8%, driven by higher revenue. Operating expenses rose to $210 million, including significant non-cash impairment charges.
Non-GAAP Earnings
On a non-GAAP basis, Azenta Inc. reported an operating loss of $6 million, with an operating margin improvement of 530 basis points year over year. The gross margin was 44.3%, up 310 basis points, and adjusted EBITDA was $9 million, reflecting a 750 basis points improvement. Non-GAAP diluted EPS was $0.05, compared to ($0.06) in the same quarter last year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2401 M
Market cap (USD)
338,120
Daily traded volume (Shares)
50.51 / 48.46
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
